Table 2.
Baseline evaluation | Follow-up evaluation | p-value | |
---|---|---|---|
Age of start therapy (years) | 8.65 + 2.81 | 11.17 + 3.0 | 0.023 |
Years of therapy | 2.41 + 1.86 | – | |
SDS of height | −2.56 + 1.10 | −1.96 + 1.24 | > 0.05 |
Growth velocity (cm/year) | 4.10 + 1.17 | 6.76 + 3.02 | 0.044 |
Target height | 160.51 + 6.64 | – | |
Bone age (years) | 7.15 + 2.84 | 11.44 + 4.10 | 0.010 |
IGF-1 (ng/ml) | 168.20 + 99.20 | 320.70 + 151.20 | 0.032 |
Percentage of adherence | – | 92.20 + 8.90 | – |
Missing doses/month | – | 1.20 + 1.35 | – |
Significant entries were italicized